Pink viagra (chemical compound to the left!) was voted down, 11-0, by the federal advisory panel that was reviewing it last week (background here). The recommendation goes to FDA to make the final decision. Meika Loe recommended this article by Susan Perry titled, “Hunt (and hype) for a ‘pink Viagra’ continues despite advisory panel’s rejection of flibanserin.” The article offers details of the comments from Amy Allina, program director of the National Women’s Health Network, but one highlight is here:

The “failure to show that [flibanserin] increases desire highlights the trouble with the push to put a label of disorder, dysfunction or disease on women’s problems with sex,” said Allina in her statement to the FDA’s panel. “There is no empirical evidence to establish a single, normal level of sexual desire for women….

–Virginia Rutter